ASH Annual Meeting and Exposition
ASH Annual Meeting and Exposition
January 05, 2016
1 min watch
Save

VIDEO: Midostaurin could be ‘game changer’ in FLT3-mutated AML

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

ORLANDO, Fla. ― Hetty Carraway, MD, provides perspective on a plenary abstract from the ASH Annual Meeting and Exposition that showed the addition of midostaurin to standard induction chemotherapy prolonged survival in younger adults with FLT3-mutated acute myeloid leukemia.